Skip to main content
OpenTrials
Completed

NCT Number: NCT06489704

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live >2500 m on pulmonary artery pressure (PAP)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

High Altitude Pulmonary Hypertension Altitude Sickness Cardiovascular Diseases Hypertension Hypertension, Pulmonary Hypoxia Lung Diseases Pathological Conditions, Signs and Symptoms Pulmonary edema of mountaineers Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aksay Medical Center

Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan, Kyrgyzstan

About this study

This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA >30 mmHg who permanently live at HA >2500 m will have pulmonary arterial pressure (PAP) assessed by echocardiography near their living altitude in Aksay at 3200 m and at 760 m in Bishkek the day after the first and the seventh night after relocation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Permanently living >2500 m
  • HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
  • Written informed consent

Exclusion criteria

  • Highlanders who cannot follow the study investigations,
  • Patients with moderate to severe concomitant lung disease (FEV1<70% or forced vital capacity <70%), severe parenchymal lung disease, heavy smoking >20 cigarettes/day or >20 pack-years.
  • Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
  • Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Treatment and study plan

echocardiography

Other

Echocardiography will be performed according to clinical standards

Primary outcomes

  1. Change in Pulmonary artery Pressure (PAP) after the first night at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 at 760 m vs. 3200 m

    Change in RV/RA in mmHg assessed by echocardiography between LA (760 m) vs High altitude (3200 m)

Secondary outcomes

  1. Change in Pulmonary artery Pressure (PAP) after seven nights at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 7 at 760 m vs. 3200 m

    Change in RV/RA in mmHg assessed by echocardiography between LA (760 m) vs High altitude (3200 m)

  2. Cardiac output at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in cardiac output in l/min assessed by echocardiography between LA (760 m) vs HA (3200 m)

  3. Tricuspid pressure gradient by echocardiography at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Tricuspid pressure gradient assessed by echocardiography between LA (760 m) vs HA (3200 m)

  4. Tricupsid annular plane systolic excursion by echocardiography at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Tricupsid annular plane systolic excursion assessed by echocardiography between LA (760 m) vs HA (3200 m)

  5. pH by arterial blood gases at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in pH by arterial blood gases assessed between LA (760 m) vs HA (3200 m)

  6. partial pressure of oxygen (PaO2) by arterial blood gases at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in partial pressure of oxygen (PaO2) assessed by arterial blood gases between LA (760 m) vs HA (3200 m)

  7. partial pressure of carbon dioxide (PaCO2) by arterial blood gases at 760 m (LA) vs at 3200 m (HA)

    Time frame: after the first and seventh night at LA

    Change in partial pressure of carbon dioxide (PaCO2) assessed by arterial blood gases partial pressure of carbon dioxide (PaCO2) between LA (760 m) vs HA (3200 m)

  8. Change in right to left heart diameter ratio at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in right to left heart diameter ratio assessed by echocardiography between LA (760 m) vs HA (3200 m)

  9. Change in right atrial area at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in right atrial area by echocardiography between LA (760 m) vs HA (3200 m)

  10. Change in right heart strain at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in right heart strain by echocardiography between LA (760 m) vs HA (3200 m)

  11. Change in ECG morphology at 760 m (LA) vs at 3200 m (HA)

    Time frame: day 2 and 7 at 760 m vs. 3200 m

    Change in ECG morphology and QT-interval by 12-lead ECG between LA (760 m) vs HA (3200 m)

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

Comparative Study of Pulmonary Artery Pressure (PAP) Assessed by Echocardiography in Patients With High Altitude Pulmonary Hypertension (HAPH) Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude (HA) at 3200 m vs. at Low Altitude (LA) at 760 m

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 8, 2024
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.